Physician profile
Catherine Laruffa
NPI 1972502789
$54,987.44
in general payments reported to CMS, 2019-2025
69 companies · $8,766 in 2025
The $8,766 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,322 · 2020: $2,193 · 2021: $3,667 · 2022: $5,039 · 2023: $25K · 2024: $7,179 · 2025: $8,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $11K · Consulting Fee: $2,250 · Travel and Lodging: $2,219 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,287.50 |
| Food and Beverage | $10,558.58 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $2,219.08 |
| Education | $451.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,945.43 | 2019-2025 | |
| Novo Nordisk INC | $3,870.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,098.87 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Teva Pharmaceuticals USA, INC. | $1,915.36 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $1,177.04 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $1,062.10 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $902.97 | 2019-2022 | |
| Lilly USA, LLC | $886.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $619.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.90 | 2019-2025 | Xifaxan, Cycloset, Relistor |
| Astellas Pharma US INC | $471.29 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $459.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $452.00 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $444.29 | 2024-2025 | Zenpep, Vowst |
| Sunovion Pharmaceuticals INC. | $430.77 | 2020-2022 |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Laruffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.